These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26728875)

  • 21. Erythropoietin-induced treatment costs in patients suffering from renal anemia - a comparison between biosimilar and originator drugs.
    Hörbrand F; Rottenkolber D; Fischaleck J; Hasford J
    Gesundheitswesen; 2014 Nov; 76(11):e79-84. PubMed ID: 24493578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
    Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
    Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Switching from one drug therapy to another with the same therapeutic indication without harms.].
    Belleudi V; Addis A
    Recenti Prog Med; 2017 Nov; 108(11):451-453. PubMed ID: 29149162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients.
    Icardi A; Sacco P; Salvatore F; Romano U
    J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Biosimilar Prescription Targets for Erythropoiesis-Stimulating Agents on the Prescribing Behavior of Physicians in Germany.
    Birkner B; Blankart KE
    Value Health; 2022 Sep; 25(9):1528-1538. PubMed ID: 35525830
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.
    Macdougall IC; Ashenden M
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):117-30. PubMed ID: 19233071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices.
    Curto S; Ghislandi S; van de Vooren K; Duranti S; Garattini L
    Health Policy; 2014 Jun; 116(2-3):182-7. PubMed ID: 24602376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
    Carrera F; Disney A; Molina M
    Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilar switching and related medical liability.
    Rocco P; Selletti S; Minghetti P
    J Forensic Leg Med; 2018 Apr; 55():93-94. PubMed ID: 29476937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving treatment strategies for anaemia in cancer: experience with epoetin beta.
    Aapro M; San Miguel J
    Oncology; 2004; 67 Suppl 1():17-22. PubMed ID: 15486449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical safety of biosimilar recombinant human erythropoietins.
    Abraham I; MacDonald K
    Expert Opin Drug Saf; 2012 Sep; 11(5):819-40. PubMed ID: 22880621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom.
    Langman M; Kahler KH; Kong SX; Zhang Q; Finch E; Bentkover JD; Stewart EJ
    Pharmacoepidemiol Drug Saf; 2001; 10(6):517-24. PubMed ID: 11828834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
    Lonnemann G; Wrenger E
    Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
    Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique].
    Bouchet JL; Brunet P; Canaud B; Chanliau J; Combe C; Deray G; Houillier P; Kourilsky O; Ledneva E; Niaudet P; Ortiz JP; Pavlovic M; Ryckelynck JP; Singlas E; Verhelst D; ; ;
    Nephrol Ther; 2009 Feb; 5(1):61-6. PubMed ID: 19084489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.
    Pujade-Lauraine E; Topham C
    Oncology; 2005; 68(2-3):122-9. PubMed ID: 16015034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.